Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.

A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the ...

The venture aims to advance MeiraGTx’s Parkinson’s gene therapy through Phase III trials with up to $430m in funding from ...

Patients who continued Ozempic through total joint arthroplasty had higher risk for complications compared with those who stopped GLP-1RAs before surgery.

At the pace with which the proportion of overweight people is growing, half of Nepal’s adult population will be obese by 2050 ...

GLP-1RAs, a class of glucose-lowering medication used to treat diabetes and obesity, may offer antidepressant effects. UF ...

As health care costs continue to rise and the burden of chronic disease grows, data-driven insights will be essential in ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.